Iovance Biotherapeutics to Present at Upcoming Conferences
Iovance Biotherapeutics will webcast two September 2026 investor conference appearances by senior leadership for remote and replay viewing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Iovance Biotherapeutics (IOVA)/b) announced that senior leadership will present at two investor conferences in September 2026.The company will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026, at 11:00 a.m. ET in Boston, MA, and deliver a presentation at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 4:00 p.m. ET in New York, NY. A live and archived webcast of both events will be available on the company’s investor relations website.
Details
News Market Reaction – IOVA
On Sep 4, the day this news came out, IOVA closed 1.03% above the previous close.
Data tracked by StockTitan Argus for the Sep 4 session.
Key Figures
- Conference Edition
- 21st annual
- Wells Fargo Healthcare Conference
- Presentation Date
- September 10, 2026
- Wells Fargo fireside chat
- Presentation Time
- 11:00 a.m. ET
- Wells Fargo fireside chat
- Conference Edition
- 28th annual
- H.C. Wainwright Global Investment Conference
- Presentation Date
- September 15, 2026
- H.C. Wainwright presentation
- Presentation Time
- 4:00 p.m. ET
- H.C. Wainwright presentation
Historical Context
-
Stock options covering 240,135 shares were granted to twenty new non-executive employees.
-
Record second-quarter revenue and narrowed net loss accompanied corporate and regulatory updates.
-
The company scheduled its second-quarter financial results and corporate-update conference call.
-
Stock options covering 139,930 shares were granted to seventeen new non-executive employees.
-
Inducement stock options covered 140,860 shares and vested over three years.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
tumor infiltrating lymphocyte medical
polyclonal medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN CARLOS, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences:
- Wells Fargo 21st Annual Healthcare Conference
Fireside Chat: September 10, 2026, at 11:00 a.m. ET
Boston, MA
- H.C. Wainwright 28th Annual Global Investment Conference
Presentation: September 15, 2026, at 4:00 p.m. ET
New York, NY
The live and archived webcast will be available at https://ir.iovance.com/news-events/events-presentations.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at more than 95 authorized treatment centers. The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. For more information, please visit www.iovance.com.
Amtagvi® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.
Information on Iovance’s broad, industry-leading patent portfolio is available on the Intellectual Property page on www.iovance.com.
Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “achievable,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
CONTACTS
Investors
IR@iovance.com
650-260-7120 ext. 150
Media
PR@iovance.com
650-260-7120 ext. 150
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will Iovance Biotherapeutics (IOVA) present at the Wells Fargo 21st Annual Healthcare Conference?
Iovance Biotherapeutics senior leadership plans to participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026, at 11:00 a.m. ET in Boston, MA.
What is the date and time of Iovance Biotherapeutics’ presentation at the H.C. Wainwright 28th Annual Global Investment Conference (IOVA)?
The company is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 4:00 p.m. ET in New York, NY.
How can investors access the webcasts of Iovance Biotherapeutics’ September 2026 conference presentations (IOVA)?
Both the live and archived webcasts of Iovance Biotherapeutics’ presentations will be available through the events and presentations section of its investor relations website at https://ir.iovance.com/news-events/events-presentations.
Where will the Iovance Biotherapeutics (IOVA) September 2026 investor presentations take place?
The Wells Fargo 21st Annual Healthcare Conference fireside chat will be held in Boston, MA, and the H.C. Wainwright 28th Annual Global Investment Conference presentation will occur in New York, NY.